miRecule Raises $5.7 M in Seed Funding
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

miRecule Raises $5.7 M in Seed Funding

Pharma Tech Outlook | Friday, June 04, 2021

The miRecule’s DREAmiR discovery platform was developed in partnership with the National Institutes of Health in Bethesda, Maryland, over a decade of research.

FREMONT, CA: miRecule (miRecule), up-and-coming biotech focusing on the development of cutting-edge RNA treatments, announced that it has raised 5.7 million dollars in seed funding. Alexandria Venture Investments led the investment round, which included Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors and support from the Maryland Momentum Fund and the FSHD Society. The National Cancer Institute has provided a non-dilutive 2 million dollar Phase II SBIR grant.

“miRecule will utilize the funding to drive its lead microRNA therapy (MC-30) towards clinical development for head & neck cancer, the 6th most common form of cancer worldwide. We are hopeful MC-30 could be a real game-changer. By correcting the underlying mutation that creates resistance to treatment, we think we can triple response rates and give years of quality life back to many patients,” commented Anthony Saleh, CEO, miRecule.

The miRecule’s DREAmiR discovery platform was developed in partnership with the National Institutes of Health in Bethesda, Maryland, over a decade of research. DREAmiR combines genomic and clinical data from thousands of patients to uncover the genetic drivers of disease and then creates RNA therapies to fix those faults directly. MiRecule’s platform is being used to treat various illnesses, including cancer, muscular dystrophy, and even viruses like HIV and COVID-19.

“miRecule has also utilized DREAmiR to develop MC-DX4, an antisense oligonucleotide treatment for Facioscapulohumeral Muscular Dystrophy (FSHD). FSHD is one of the most common muscular dystrophies, with over 40,000 patients in the US (many of whom are children). Currently, there are no FDA approved treatments for FSHD. The FSHD Society is excited to be a funding partner in this endeavor, which aligns strongly with our mission to reduce obstacles inherent in the clinical & regulatory process for FSHD,” said Mark Stone, CEO, FSHD society.

“miRecule spun out of the NIH into BioHealth Innovations (BHI) incubator in 2017. BHI is proud to have been a co-founder with miRecule, and assist in their fundraising and growth here in Maryland. Anthony is a role model having transitioned from an academic scientist to a successful entrepreneur, and we are glad to have supported him through this process,” said Rich Bendis, CEO, BHI.

“We think miRecule’s therapeutics will vastly improve the lives of patients by changing the course of their serious diseases,” said Dr. Rami El Assal, Managing Partner & Co-founder of Boutique Venture Partners.

“miRecule’s innovative, data-driven discovery engine shows true platform potential for the next generation of RNA therapeutics. We were really glad to have miRecule participate in Alexandria’s Seed Capital Platform, and ultimately participate in the company’s seed round,” said Conley Jones from Alexandria Venture Investments.

Weekly Brief

Read Also